Skip to main content
PROTIA INC. logo

PROTIA INC. — Investor Relations & Filings

Ticker · 303360 ISIN · KR7303360002 KO Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2018-12-26 Audit Report / Informat…
Country KR South Korea
Listing KO 303360

About PROTIA INC.

https://www.protia.co.kr/en/main

PROTIA INC. is an in-vitro diagnostics (IVD) company that develops, manufactures, and sells a wide range of diagnostic kits and instruments. The company is particularly known for its flagship product, PROTIA Allergy-Q, a multiplex allergy diagnostic kit for the quantitative determination of allergen-specific IgE. Its portfolio also includes point-of-care testing (POCT) solutions like the ImmuneCheck IgG kit, diagnostic tests for infectious and autoimmune diseases, cancer, and antibiotic susceptibility, as well as the ANITIA line for companion animal allergy testing. In addition to its product offerings, PROTIA provides comprehensive protein analysis services, including LC-MS/MS and characterization analysis, aiming to contribute to early disease prediction and diagnosis through innovative technology.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2017.12)
Audit Report / Information Classification · 1% confidence The document is a 'Correction Report' (정정신고) for an Audit Report (감사보고서) of ProteomeTech. It explicitly details corrections made to financial statements (Balance Sheet, Income Statement, etc.) due to accounting errors regarding the capitalization of diagnostic reagent development costs. It includes the independent auditor's report, financial statements, and notes. Since it is a formal audit-related filing containing corrected financial statements and audit opinions, it falls under the Audit Report category. FY 2017
2018-12-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of a 11.57% stake in ProteomeTech by KB12-1 Venture Fund due to a new listing on the KONEX exchange. This document type is specifically used for major shareholding notifications (crossing thresholds) and is classified as MRQ.
2018-12-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding status of 'KB12-1 Venture Fund' in the company 'ProteomeTech'. This type of filing is a standard disclosure required when a major shareholder or insider changes their ownership stake, which falls under the category of Major Shareholding Notification (MRQ).
2018-12-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document is used to notify the market when an entity acquires 5% or more of a company's shares. It is not an annual report, earnings release, or announcement, but a specific regulatory disclosure of share ownership. Therefore, it falls under the 'Major Shareholding Notification' category.
2018-12-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by '한국투자 글로벌 제약산업 육성 사모투자전문회사' in the company '프로테옴텍'. This type of filing is specifically used to notify the market when an entity crosses a significant shareholding threshold (typically 5% or more). In the provided classification schema, this corresponds to a 'Major Shareholding Notification'.
2018-12-21 Korean
[기재정정]감사보고서 (2017.12)
Audit Report / Information Classification · 1% confidence The document is a 'Correction Report' (정정신고) for an Audit Report (감사보고서) originally submitted on April 6, 2018. It details corrections made to the 2017 financial statements due to accounting errors regarding the capitalization of diagnostic reagent development costs. The document includes the independent auditor's report, corrected financial statements (balance sheet, income statement, etc.), and notes. Since it is a formal audit report document (even if it is a correction/restatement), it falls under the Audit Report category. FY 2017
2018-10-31 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.